Document Detail

Treatment of preeclampsia and eclampsia.
MedLine Citation:
PMID:  1611813     Owner:  NLM     Status:  MEDLINE    
The characteristics and treatment of preeclampsia and eclampsia are reviewed. Risk factors for preeclampsia include (1) nulliparity, (2) a mother or sister(s) with a history of the disorder, (3) essential hypertension or renal disease, or (4) a twin or molar pregnancy. Preeclampsia is diagnosed when the systolic blood pressure (BP) increases by 30 mm Hg or the diastolic BP increases by 15 mm Hg after the 20th week of gestation and the BP rise is accompanied by edema, proteinuria, or both. Severe preeclampsia is diagnosed when the BP reaches or exceeds 160 mm Hg systolic or 110 mm Hg diastolic after bed rest. Eclampsia is the occurrence of seizures (in the preeclamptic patient) that cannot be attributed to other causes; it occurs in about 0.2% of preeclamptic patients. Magnesium sulfate (in the injectable, hydrated form) is the agent used most often for seizure prophylaxis in the preeclamptic patient in the United States. It is also used widely to control seizures once they develop. In the United States, diazepam is used to supplement magnesium sulfate if necessary to control seizures, but its use is not routine. Among antihypertensive agents, i.v. hydralazine is preferred in this country to control blood pressure in the severely preeclamptic or eclamptic patient. Several studies provide promising evidence that low-dose aspirin (60-150 mg daily beginning at 28-30 weeks of gestation) prevents preeclampsia in women who are at risk for its development. Until additional comparative studies are completed, magnesium sulfate and hydralazine will remain the standard of care for the treatment of preeclampsia in the United States.
J McCombs
Related Documents :
3236323 - Efficacy of once daily nitrendipine in essential hypertension--a study using ambulatory...
10574413 - Long-term safety and antihypertensive efficacy of irbesartan: pooled results of five op...
7370083 - Increased vascular collagen and elastin synthesis in experimental atherosclerosis in th...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Clinical pharmacy     Volume:  11     ISSN:  0278-2677     ISO Abbreviation:  Clin Pharm     Publication Date:  1992 Mar 
Date Detail:
Created Date:  1992-07-24     Completed Date:  1992-07-24     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  8207437     Medline TA:  Clin Pharm     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  236-45     Citation Subset:  IM    
College of Pharmacy, University of Georgia, Athens 30602.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antihypertensive Agents / therapeutic use
Aspirin / therapeutic use
Diazepam / therapeutic use
Eclampsia / drug therapy*
Magnesium Sulfate / pharmacology,  therapeutic use*
Phenytoin / therapeutic use
Pre-Eclampsia / drug therapy*
Risk Factors
Reg. No./Substance:
0/Antihypertensive Agents; 439-14-5/Diazepam; 50-78-2/Aspirin; 57-41-0/Phenytoin; 7487-88-9/Magnesium Sulfate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies.
Next Document:  Systemic absorption of intraperitoneal antimicrobials in continuous ambulatory peritoneal dialysis.